ICES13

Unassigned

New Medicines

Mild-to-moderate stress incontinence in women - second-line

Information

ATMP
Innovacell Biotechnologie
Not Known

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

An autologous myoblast cell-based therapy which is thought to result in functional improvement of the female urethral closure mechanism
UK prevalence rates of urinary incontinence are between 5-69% in women [1].
Mild-to-moderate stress incontinence in women - second-line
Implantation

Evidence based evaluations